The medical management of prostate cancer: A multidisciplinary team approach

BJU International

Volumn 99, Issue 1, 2007, Pages 22-27

  Sternberg, Cora N ^a   Krainer, Michael ^b   Oh, William K ^c   Bracarda, Sergio ^d   Bellmunt, Joaquim ^e   Ozen, Haluk ^f   Zlotta, Alexandre ^g   Beer, Tomasz M ^h   Oudard, Stephane ⁱ   Rauchenwald, Michael ^j   Skoneczna, Iwona ^k   Borner, Markus M ^l   Fitzpatrick, John M ^m  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^e HOSPITAL DEL MAR   (Spain)

^f HACETTEPE UNIVERSITY   (Turkey)

^g ERASME HOSPITAL   (Belgium)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^j DANUBE HOSPITAL   (Austria)

^k INSTITUTE OF ONCOLOGY   (Poland)

^l UNIVERSITY OF BERN   (Switzerland)

^m MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

more..

Author keywords

Chemotherapy; Multidisciplinary; Prostate cancer

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; ATRASENTAN; BEVACIZUMAB; BICALUTAMIDE; BORTEZOMIB; CALCITRIOL; CETUXIMAB; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; DOCETAXEL; EPOTHILONE DERIVATIVE; ESTRAMUSTINE; ESTROGEN; GEFITINIB; GONADORELIN; GONADORELIN DERIVATIVE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMATINIB; MITOXANTRONE; NAVELBINE; OBLIMERSEN; PREDNISONE; SATRAPLATIN; SORAFENIB; SUNITINIB; THALIDOMIDE; TRASTUZUMAB; UNINDEXED DRUG; VATALANIB;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HORMONAL THERAPY; HORMONE RESISTANCE; HUMAN; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SHORT SURVEY; SOLID TUMOR; TESTOSTERONE BLOOD LEVEL;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III; HUMANS; MALE; PATIENT CARE TEAM; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 33845487164     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06477.x     Document Type: Short Survey

References (30)

1. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12
2. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitroxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20
3. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-7
4. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351: 125-35
5. Freedland SJ, Humphreys EB, Mangold LA et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-9
6. Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 2005; 23: 6992-8
7. Bauer JJ, Connelly RR, Sesterhenn IA et al. Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. Cancer 1997; 79: 952-62
8. Potter SR, Miller MC, Mangold LA et al. Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. Urology 1999; 54: 791-5
9. D'Amico AV, Whittington R, Malkowicz SB et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 2000; 18: 1164-72
10. Stephenson AJ, Shariat SF, Zelefsky MJ et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004; 291: 1325-32
11. Bolla M, van Poppel H, Collette L et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-8
12. Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgenindependent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-7
13. Kelly WK, Scher HI. Prostate cancer: how can a common disease be so controversial? Curr Opin Oncol 1994; 6: 318-31
14. Joyce R, Fenton MA, Rode P et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998; 159: 149-53
15. Kassouf W, Tanguay S, Aprikian AG. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol 2003; 169: 1742-4
16. Miyake H, Hara I, Eto H. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU Int 2005; 96: 791-5
17. Ryan CJ, Small EJ. Secondary hormonal manipulations in prostate cancer. Curr Oncol Rep 2005; 7: 228-33
18. Berthold DR, Sternberg CN, Tannock IF. Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol 2005; 23: 8247-52
19. Sternberg CN. Satraplatin in the treatment of hormone-refractory prostate cancer. BJU Int 2005; 96: 990-4
20. Bhandari MS, Hussain M. Epothilones and the next generation of phase III trials for prostate cancer. BJU Int 2005; 96: 296-302
21. Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 2003; 89: 968-70
22. Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 2004; 91: 1425-7
23. Miller K, Wülfing C, Lehmann J et al. Weekly docetaxel plus estramustine for hormone-refractory prostate cancer (HRPC) with intermittent repetition. Preliminary results of a multicenter Phase II study (AUO AP33/02). J Clin Oncol 2005; 23 (Suppl): 406S
24. Rosenbaum E, Kibel A, Roth B et al. A pilot multicenter phase II study of adjuvant Docetaxel (D) for high risk prostate cancer (PC) patients (pts) after radical prostatectomy (RP): Preliminary data. J Clin Oncol 2005; 23 (Suppl): 394S
25. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999; 17: 1499-507
26. Sternberg CN. Hormonal therapy and radiation therapy in the treatment of locally advanced prostate cancer. Mol Urol 1999; 3: 227-30
27. Febbo PG, Richie JP, George DJ et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005; 11: 5233-40
28. Goodin S, Medina P, Capanna T et al. Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer. J Clin Oncol 2005; 23: 3352-7
29. Hussain A, Dawson N, Amin P et al. Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer. J Clin Oncol 2005; 23: 2789-96
30. Slovin SF, Carducci MA, Beekman KW et al. The Men's cycle plus docetaxel (Doc) in prostate cancer patients with rising PSAs in the non-castrate state. J Clin Oncol 2005; 23 (Suppl): 393S